Neostigmine is not an antagonist of rocuronium because it does not compete with rocuronium for the muscle end-plate receptor site. Neostigmine inhibits acetylcholinesterase, which allows acetylcholine to compete effectively with rocuronium and other nondepolarizing muscle relaxants for the receptor, leading to a recovery of muscle tone. Therefore, its effect is at least a partial form of indirect antagonism.
If you want to change selection, open document below and click on "Move attachment"
pdf
cannot see any pdfs
Summary
status
not read
reprioritisations
last reprioritisation on
suggested re-reading day
started reading on
finished reading on
Details
Discussion
Do you want to join discussion? Click here to log in or create user.